← All trials
NCT01045382
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2010
- Primary completion
- Jul 1, 2021
- Completion date
- Jul 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LiegeLead sponsor
- CHU Mont-GodinneOverall official - principal investigator
- Free University of BrusselsCollaborator
- University of LiegeReponsible party - principal investigator
- ZNA AntwerpenOverall official - principal investigator
- AZ Sint-JanOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Free University of BrusselsOverall official - principal investigator
- Universitair Ziekenhuis GentOverall official - principal investigator
- Chu De LiègeOverall official - principal investigator
- Chu De LiègeStudy chair
- Ghent UniversityCollaborator
- ZNA AntwerpenCollaborator
- AZ Sint-JanCollaborator
- University of LondonOverall official - principal investigator
- University of AntwerpOverall official - principal investigator
- University of AntwerpCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.